BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 741533)

  • 1. Cellular cytotoxicity in transitional cell carcinoma of the human urinary bladder - a summary.
    Perlmann P; Troye M; Pape G; Blomgren H; Johansson B
    Urol Res; 1978; 6(4):207-9. PubMed ID: 741533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytotoxicity in vitro of blood lymphocytes from bladder cancer patients and controls to allogeneic or autologous tumor cells derived from established cell lines or short-term cultures.
    Troye M; Vilien M; Pape GR; Perlmann P
    Int J Cancer; 1980 Jan; 25(1):33-43. PubMed ID: 7399743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A 51chromium isotope release assay for detecting cytotoxicity to human bladder carcinoma.
    O'Toole C
    Int J Cancer; 1977 Mar; 19(3):324-31. PubMed ID: 844912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cellular cytotoxicity in vitro in transitional cell carcinoma of the human urinary bladder: 51Cr-release assay.
    Troye M; Perlmann P; Larsson A; Blomgren H; Johansson B
    Int J Cancer; 1977 Aug; 20(2):188-98. PubMed ID: 892930
    [No Abstract]   [Full Text] [Related]  

  • 5. Disease-related lymphocyte cytotoxicity in rats bearing transitional cell carcinoma of bladder. Effect of immunomodulators.
    Moroz C; Madgar I; Twig S; Lindner A; Many M
    Int J Cancer; 1982 Jun; 29(6):667-72. PubMed ID: 6980847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lymphocyte-mediated lysis of tumor cells in vitro (ADCC), induced by serum antibodies from patients with urinary bladder carcinoma or from controls.
    Troye M; Hansson Y; Paulie S; Perlmann P; Blomgren H; Johansson B
    Int J Cancer; 1980 Jan; 25(1):45-51. PubMed ID: 7399744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specificity of in vitro cellular cytotoxicity against transitional cell carcinoma cell line T-24.
    Catalona WJ; Oldham RK; Djeu JY; Herberman RB; Cannon GB
    Surg Forum; 1975; 26():122-4. PubMed ID: 56048
    [No Abstract]   [Full Text] [Related]  

  • 8. A follow-up study of urinary bladder patients tested for tumour-related lymphocyte-mediated cytotoxicity.
    Larsson A; Näslund I; Troye M
    Cancer Immunol Immunother; 1982; 14(2):82-5. PubMed ID: 6965230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cell-mediated tumour immunity in patients with transitional cell carcinoma of the urinary bladder.
    Bubeník J
    Int Urol Nephrol; 1975; 7(4):297-302. PubMed ID: 1107249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Humoral and cellular immune reactions against tumor cells in patients with urinary bladder carcinoma. Correlation between direct and antibody-dependent cell-mediated cytotoxicity.
    Hansson Y; Paulie S; Larsson A; Lundblad ML; Perlmann P; Näslund I
    Cancer Immunol Immunother; 1983; 16(1):23-9. PubMed ID: 6556949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor-associated and spontaneous lymphocyte-mediated cytotoxicity against cell lines derived from human urothelium.
    Vilien M
    Dan Med Bull; 1985 Aug; 32(4):199-218. PubMed ID: 3899526
    [No Abstract]   [Full Text] [Related]  

  • 12. Cellular immunity to transitional cell carcinoma of the urinary bladder. III. Effects of hydrostatic pressure therapy.
    O'Toole C; Helmstein K; Perlmann P; Moberger G
    Int J Cancer; 1975 Sep; 16(3):413-26. PubMed ID: 1176202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro cytotoxicity studies in bladder and renal cell cancer.
    Elhilali MM; Nayak SK
    Urology; 1976 May; 7(5):488-91. PubMed ID: 1274005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Classification of the bladder cancer patient based on in vitro measurements of the immune response.
    Lange PH; Hakala TR; Fraley EE
    Cancer Res; 1977 Aug; 37(8 Pt 2):2885-90. PubMed ID: 326395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation by the protein-bound polysaccharide PSK (krestin) of cytotoxic lymphocytes that act on fresh autologous tumor cells and T24 human urinary bladder transitional carcinoma cell line in patients with urinary bladder cancer.
    Mizutani Y; Yoshida O
    J Urol; 1991 May; 145(5):1082-7. PubMed ID: 2016797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunologic evaluation of human bladder cancer: in vitro studies.
    Elhilali MM; Nayak SK
    Cancer; 1975 Feb; 35(2):419-31. PubMed ID: 1111918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Membrane-associated antigens on tumor cells from transitional-cell carcinoma of the human urinary bladder. I. Immunological characterization by xenogeneic antisera.
    Schneider MU; Troye M; Paulie S; Perlmann P
    Int J Cancer; 1980 Aug; 26(2):185-92. PubMed ID: 7203712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation by cis-diamminedichloroplatinum (II) of the susceptibilities of human T24 lined and freshly separated autologous urinary bladder transitional carcinoma cells to peripheral blood lymphocytes and lymphokine activated killer cells.
    Mizutani Y; Nio Y; Yoshida O
    J Urol; 1992 Feb; 147(2):505-10. PubMed ID: 1732632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lymphocyte antibody interaction in cytotoxicity against human transitional cell carcinoma.
    Hakala TR; Lange PH; Castro AE; Elliott AY; Fraley EE
    J Urol; 1975 May; 113(5):663-7. PubMed ID: 1168732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon-alpha-2b enhances the natural killer activity of patients with transitional cell carcinoma of the bladder.
    Carballido JA; Moltó LM; Manzano L; Olivier C; Salmerón OJ; Alvarez de Mon M
    Cancer; 1993 Sep; 72(5):1743-8. PubMed ID: 8348503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.